home / stock / bioaf / bioaf news

BIOAF News and Press, Bioasis Technologies Inc From 05/10/22

Stock Information
Company Name: Bioasis Technologies Inc
Stock Symbol: BIOAF
Market: OTC
Website: bioasis.us
Menu
BIOAF BIOAF Quote BIOAF Short BIOAF News BIOAF Articles BIOAF Message Board
Get BIOAF Alerts

News, Short Squeeze, Breakout and More Instantly...
BIOAF - Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics a...
BIOAF - Bioasis enters into research collaboration with Janssen for its xB3 platform

Biopharmaceutical company Bioasis Technologies (OTCQB:BIOAF) on Monday entered into a research collaboration with Johnson & Johnson's (JNJ) Janssen Biotech. As per the agreement, Janssen will have the option to research, develop and commercialize products based on Bioasis' xB3 p...

BIOAF - Bioasis Enters Into Research Collaboration With Janssen

NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics...

BIOAF - Bioasis to Attend and Present at Upcoming Industry Conference

NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of...
BIOAF - Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021

NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics ...

BIOAF - Bioasis to Attend and Present at Upcoming Industry Conferences

NEW HAVEN, Conn., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of ...

BIOAF - Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021

NEW HAVEN, Conn., Oct. 28, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...
BIOAF - Bioasis to Attend Upcoming Industry Conferences

NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of the...

BIOAF - Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor

NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...

BIOAF - Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³(TM) Fusion Protein Comprising Iduronate-2-sulfatase

NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...
Previous 10 Next 10